JPRN-jRCT2080222670未知3 期
Prospectiove, single-arm, Open-label, multi-center study to assess the efficacy, safety, and tolerability of ACT-385781A in Japanese children with pulmonary arterial hypertension.
Actelion Pharmaceuticals Japan Ltd.0 个研究点目标入组 3 人开始时间: 2014年11月27日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 <= 14age old（—）
- 性别
- All
入选标准
- •Idiopathic PAH, Heritable PAH, PAH associated with CHD
排除标准
- •Patients with respiratory and/or cardiovascular distress in need of emergency care, etc.
研究者
相似试验
进行中（未招募）
1 期
Single-arm pharmacokinetic phase 2a study of a single dose intravenous human plasma-derived C1-INH involving 20 HAE type I or type II patients, aged 18 years or olderEUCTR2019-001693-28-DEOctapharma Pharmazeutika Produktionsges.m.b.H.20
已完成
2 期
Pharmacokinetics and safety of IV Injection of OCTA-C1-INH in hereditary angioedemaISRCTN36746902Octapharma (Austria)20
已完成
不适用
Prospective, multi-center, single-arm, open-label, observational study forEvaluation of Performance and Safety of the BICOM optima / BICOMoptima Mobil device for bioresonance treatment in patients with allergicrhino-conjunctivitis.J30Vasomotor and allergic rhinitisDRKS00024523Regumed- Regulative Medizintechnik GmbH127
招募中
不适用
Prospective, open-label, multicenter, single-arm, post-marketingstudy to assess the performance and safety of Vliwasorb® Prowound healingDRKS00031365ohmann & Rauscher GmbH & Co.KG135
已完成
4 期
This is multi-center, known drug with no comparator drug, clinical study to evaluate safety and efficacy of OmaliRel™ in patients with moderate to severe persistent asthma.CTRI/2021/05/033508Reliance Life Sciences Pvt Ltd220